cardiotoxicitybreast cancersurvivorsPROBLEM IDENTIFICATION: This review identifies specific cardiotoxicity related to anthracycline chemotherapy, specific risk factors related to increased anthracycline chemotherapy-induced cardiotoxicity, and underlying mechanisms of action of anthracycline chemotherapy-induced ...
This cardiotoxicity is related to a patient's cumulative lifetime dose. A patient's lifetime dose is calculated during treatment, and anthracycline treatment is usually stopped (or at least re-evaluated by the oncologist) upon reaching the maximum cumulative dose of the particular anthracycline. ...
Anthracyclines such as doxorubicin, daunorubicin, epirubicin, mitoxantrone and idarubicin are the most commonly used chemotherapy drugs in cancer. They are a known cause of cardiotoxicity (Table 1), with acute or/and subacute effects that can manifest as electrocardiographic changes, ventricular and supr...
Cancer patients receiving anthracycline-based chemotherapy are at risk to develop life-threatening chronic cardiotoxicity with the pathophysiological mechanism of action not fully understood. Besides the most common hypothesis that anthracycline-induced
In a U.S. National Health and Nutrition Examination survey of 1,807 cancer survivors followed for 7 years, 33% died of heart diseases and 51% of cancer (2). The primary cause of chemotherapy-induced cardiotoxicity is anthracycline compounds, which are used extensively to treat lymphoma, ...
D. Yellon1 Anthracycline Chemotherapy and Cardiotoxicity Cardiovascular Drugs Therapy (2017) 31:63-75 [201] G. Minotti. P. Menna. E. Salvatorelli. G. Cairo. L. Gianni. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological reviews. ...
Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Cardiotoxicity is a well-recognised complication of chemotherapy with anthracycline and/or trastuzumab, and its prevention remains an important challenge i... K Kalam,TH Marwick - ...
In order to detect, prevent or attenuate cardiotoxicity induced by anthracyclines, it is essential that all patients undergo a rigorous initial evaluation and have close monitoring under the cardiovascular point of view. Several clinical trials have shown the cardioprotective effect by non-pharmacological...
Anthracyclines, especially doxorubicin and daunorubicin, are the drugs of first choice in the treatment of patients with hematologic malignancies, soft-tissue sarcomas, and solid tumors. Unfortunately, the use of anthracyclines is limited by their dose-dependent and cumulative cardiotoxicity. The molecular...
In this regard, cardiovascular complications have emerged as a leading cause of long-term morbidity and mortality in long-term survivors of childhood cancer, likely due to exposure to anthracycline chemotherapy, and outcomes in patients with anthracycline-related cardiomyopathy remain poor. Some progress...